Navigation Links
Millennium Ranks in the Top 10 Best Biopharma Employers in the World by Science Magazine
Date:10/9/2008

CAMBRIDGE, Mass., Oct. 9 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced it has been named among the best biopharmaceutical companies in the world, according to Science magazine's annual survey of Top Employers in the biotechnology, biopharmaceutical, pharmaceutical and related industries. With a 2008 ranking of eighth, the Company is in the top ten for the first time, moving up from a 2007 ranking of 14.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080827/NEW076LOGO )

"This top ten ranking underscores Millennium's commitment not only to breakthrough science, but also to its employees and overall working environment," said Stephen Gansler, Senior Vice President, Human Resources, Millennium. "It is now more important than ever for us to keep up this positive work culture as we recruit for the hundreds of new additions over the next few months."

Respondents to the web-based survey were asked to rate companies based on 23 driving characteristics, including financial strength, easy adaptation to change and a research-driven environment. The 2008 survey sought to identify the companies with the best reputations as employers, based on nearly 4,000 survey responses from readers of Science and other respondents in industry. Twenty percent of the respondents came from outside the United States, primarily Western Europe, and 92 percent worked in private industry. For the complete business office feature with individual company rankings, please visit: http://sciencecareers.sciencemag.org/career_magazine/previous_issues/articl es/ 2008_10_10/science.opms.r0800061.

Millennium was acquired by Takeda Pharmaceutical Company Limited in May, 2008.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical co
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
2. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
3. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
4. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
5. Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
6. Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
7. Millennium Announces $200,000 Purchase Order From Greek Distributor
8. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
9. Millennium Over-Delivers on 2007 Goals and Financial Guidance
10. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
11. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... September 17, 2014 Shimadzu ... Liquid Chromatograph (2D-LC), which offers a powerful ... matrices. The system provides a new level ... which is beneficial to scientists analyzing pharmaceutical ... natural products. , Comprehensive 2D-LC combines two ...
(Date:9/17/2014)... September 17, 2014 Immunomic Therapeutics, Inc. ... Research (SBIR) grant to support the continued preclinical development ... ITI with approximately $255,000 over one year to conduct ... of food allergy, affect over one million Americans and ... allergy. Tree nut exposure is also a risk for ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics ... that develops and commercializes proprietary technologies and products for ... have been approved for trading in the ... Trading is expected to commence on September 17, 2014 ... will continue to trade on the TSX Venture Exchange ...
(Date:9/17/2014)... Angeles, CA (PRWEB) September 17, 2014 Escape ... microchip for pets which will alert owners if their pet ... using GPS from an implanted microchip in the pet’s body. ... implantable microchips for pets have been around for many years, ... and are not able to track a pet’s location or alert ...
Breaking Biology Technology:Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 2Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 3
... CROSSE, Wis., Dec. 8, 2011  Prem Rabindranauth, MD, a heart ... in La Crosse, Wis., is using an exciting ... perform heart bypass surgery. To perform MICS, a very small ... cut through the breast bone that is needed with traditional ...
... WaferGen Biosystems, Inc. (OTCBB:WGBS), an emerging genomic analysis ... its corporate presentation at the Oppenheimer 22nd Annual Healthcare ... 2011. The Company is scheduled to present ... Time.  The presentation will be webcast live and will ...
... Therapies, Inc. (OTCQB: BRTX) ("BRT") today announced that it ... University of Utah.  Pursuant to the agreement, the University ... derived from stem cells. The agreement ... strategic collaboration between BRT and the University of Utah, ...
Cached Biology Technology:Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery 2WaferGen to Present Corporate Overview at Oppenheimer Healthcare Conference 2BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah 2
(Date:9/17/2014)... Evolution and Yale University offers compelling support for the ... partially predict the likelihood of being diagnosed with mental ... life. The study analyzed medical records of 1.75 million ... 30 years, and adjusted for almost all other known ... Proceedings of the Royal Society, London B . ...
(Date:9/17/2014)... at the Catalan Institute of Oncology-Bellvitge Biomedical Research ... 5 genes differentially expressed in normal accompanying cells ... be used to classify colorectal tumors, predict the ... clinical decisions to prevent relapses. , Biomarkers ... common in our population considering both sexes. About ...
(Date:9/17/2014)... on a Carnegie expedition in Australia,s Great Barrier Reef ... since the mid-1970s. The scientists suggest that ocean acidification ... slowdown. , In a quest for historical context ... current measurements of the growth rate of a section ... more than 30 years ago. Their work is published ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Five genes to predict colorectal cancer relapses 2Coral growth rate plummets in 30-year comparison 2
... clinical trial to test a revolutionary treatment for blindness ... (University College London). The trial, funded by the Department ... could have a significant impact on future treatments for ... and children who have a condition called Leber’s congenital ...
... are an integral part of African culture, one of ... South Africa, 21st century drug therapy is used side-by-side ... plants have been used in African medicine to treat ... of the purported benefits of many plants is still ...
... brain study, even people who seemed resilient but were close to ... 11, 2001, have brains that are more reactive to emotional stimuli ... is the finding of a new Cornell study that excluded people ... (PTSD) or major depression. One of the first studies to look ...
Cached Biology News:First clinical trial of gene therapy for childhood blindness 28 plants from South Africa may hold potential for treating high blood pressure 28 plants from South Africa may hold potential for treating high blood pressure 38 plants from South Africa may hold potential for treating high blood pressure 4Traumas like Sept. 11 make brains more reactive to fear 2
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... Abpromise for all tested applications). ... to KLH derived from within residues 400 ... acid sequence is proprietary)(Peptide available as ... ID: 55693 Swiss ...
Perm/Wash Buffer 250 Tests...
Mouse monoclonal to OCIL ( Abpromise for all tested applications)....
Biology Products: